DayOne Health 4.0, the six-month hybrid accelerator program for health tech startups at the interface with Pharma in the Basel Area, is now kicking off its 2024 edition.
Whether it’s in advancing clinical biomarkers, reinventing clinical trials or enhancing patient experience, we are proud to be working with 15 inspiring startups that are harnessing AI, data and digital tools to drive game-changing innovation in clinical development:
aimed analytics builds a SaaS platform that unlocks valuable insights from vast amounts of medical data. This empowers pharma companies, researchers, institutions, and healthcare professionals to make data-driven decisions, develop drugs and therapies more efficiently, and drive scientific discoveries. 
BioT is the infrastructure for MedTech and Pharma clouds, built right from the start. Its flexible, open, and secure cloud infrastructure keeps medical data safe while enabling you to build and offer new services and capabilities right out of the box. 
Bowhead Health‘s Navigator revolutionizes clinical trial matching by reducing the time for healthcare professionals to find relevant trials to under 10 minutes. This advanced Decision Support System saves time and money for healthcare organizations, enhances patient access to innovative treatments, and accelerates enrollment for the pharmaceutical industry. 
Delve Health simplifies clinical trials with real-time data from wearable devices, patient-reported outcomes, eConsent, and automated engagement for all research stakeholders. Our platform supports decentralized and hybrid studies, patient registries, and real-world evidence studies, enhancing trial efficiency and patient engagement. 
Ephion Health has developed a patient functional capacity monitoring system based on biomechanical gait analysis using portable devices and AI. The technology allows the integration of data from different 3rd party wearables while the patient walks just 10 meters. 
Exploris Health is an AI company developing Multi-Omic-Marker Algorithms to diagnose complex diseases and provide personalized treatment recommendations. The goal is to improve patient outcomes while reducing costs of providers and healthcare systems. 
iLoF is a deep tech, digital health company pioneering Optomics®: a breakthrough Al-platform designed to accelerate the future of personalized medicine, ingesting massive amounts of data to build a comprehensive digital library of biomarkers and biological profiles. 
Miicare is a digital health company specializing in personalized care at home. The team built an advanced conversational companion and medical assistant designed to engage users in natural, meaningful and empathetic dialogues while providing emotional support and personalized health advice. 
OncoDecipher is developing an advanced AI platform dedicated to the discovery of new targets for precision oncology drug development in non-coding gene regions (“dark genome”), and to the development of highly selective and efficient new targeted therapies for patient sub-populations of hard-to-treat tumors. 
Oncoustics creates advanced AI solutions for low-cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Applying AI to RF signals, they rapidly differentiate healthy versus diseased tissues, turning any ultrasound device into a powerful virtual biopsy tool that will democratize diagnostics. 
Senseera offers a groundbreaking approach to liquid biopsy, unlocking a deeper understanding of cell states by analyzing gene expression, regulatory programs, and more, all from circulating cell-free DNA in a patient’s blood. 
Theremia has developed a platform that uses AI to create drug derivatives tailored to specific population subgroups (considering age, gender, ethnicity, disease stage, etc.), currently focusing on molecules targeting the central nervous system. 
TOM Medications has developed an app that facilitates tracking and adherence to medications. By involving patients early in the clinical development phase and iterating continuously, TOM creates a real-world data supply chain from clinical trials to post-marketing, paving the way for more accurate and effective healthcare solutions. 
VEIL.AI has developed a solution that creates high-quality, individual-level anonymized and synthetic data enabling safe use of sensitive information in various use cases, such as multi-party data collaborations, re-use of legacy data and AI algorithm development. 
Wemedoo provides unified software solutions for clinical research and practice. We integrate all clinical trial tools into a single, comprehensive system and enable digitized treatment paths, workflows, and disciplines. Our clients leverage real-time data, seamless collaboration, and AI across healthcare to achieve superior clinical advancements. ”The quality and diversity of the submissions for this year’s program were incredibly high, and I am excited to kick off the initial phase of the accelerator in September. All the companies in the cohort are bringing something of significant potential value to the healthtech space and I can’t wait to see how their journeys unfold.
Cécile TardyManager DayOne Health 4.0 Accelerator
DayOne’s expert selection panel had the tough challenge to choose only 15 companies from a total of 170 submissions, coming in from countries all around the world:
The theme of this year’s accelerator program is “Harnessing AI, data and digital tools to power clinical development”, and within that our 2024 cohort is spread across our four main areas of interest:
”DayOne Health 4.0 is now six years old and has to date accelerated a total of 38 truly inspiring healthtech startups to achieve Seed or Series A funding, or beyond. All these companies further enrich Basel Area’s expanding global network, and it is incredibly motivating for us to be able to see the ecosystem grow and evolve through the program.
Ursula CostaDirector Healthcare Innovation, DayOne
The cohort members are now starting Phase 1 of the acceleration program, which will focus on helping them to optimize the value proposition and business model of their startup. DayOne will also set them up with valuable connections with fellow startups, mentors, experts, and the various accelerator program sponsors.
At the end of the year, five of the 15 startups will be selected to advance to Phase 2, where they will work towards scaling up their business and achieving pivotal milestones. They will receive tailored mentoring and expert support, as well as in-kind services offered by DayOne and its supporting sponsors, to prepare them for collaborations with the life science industry.
Are you interested in applying for next year’s program?
If you’re a startup with a healthtech solution and aiming at collaborating with pharma companies, then the DayOne team would love to hear from you. Learn more about the DayOne Health 4.0 program here. Please feel free to express your interest here and get notified when our 2025 call opens. (NB: this link will take you to our partner F6S platform).
About DayOne
DayOne, based in Basel, is the epicenter for pioneering health tech ventures. Their core mission is to propel startups and aid corporates, providers, and payers in external innovation.
Since 2018, the DayOne Accelerator, powered by global partners, has catalyzed 87 international healthcare ventures in digital health and medtech through competitive, equity-free initiatives. Complementing this, their impactful events like BOOM Summit, Health hack and Open Mic Next in Health Series unite the health tech community, fostering change and amplifying the spirit of innovation. Rooted in the European life sciences hub, it champions collaborative innovation through an ecosystem approach.
